Marburg virus DNA vaccine - GenPhar

Drug Profile

Marburg virus DNA vaccine - GenPhar

Latest Information Update: 04 Jan 2007

Price : $50

At a glance

  • Originator GenPhar
  • Developer GenPhar; United States Army Medical Research Institute of Infectious Diseases
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Clinical Phase Unknown Marburg virus disease

Most Recent Events

  • 23 Nov 2006 Clinical trials in Marburg virus disease in USA (unspecified route)
  • 23 Oct 2002 Preclinical trials in Marburg virus disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top